LifeSpan Vision Ventures Invests in Remedium Bio
NORWALK, Conn., Sept. 10, 2024 /PRNewswire/ -- LifeSpan Vision Ventures today announced that it has closed an investment in Remedium Bio. - The biotechnology company is developing a first-in-class adjustable-dose gene therapy platform called Prometheus™, which can replace a broad range of multi-protein injection treatments with a single injection, dose adjustable, gene therapy. The treatment, which...
Study Shows Ubie Symptom Checker Accuracy Rivals Physicians, Outperforms Competitors In Providing Disease Information
Results show Ubie's differential diagnosis platform had a Top-5 hit accuracy of 63.4% and a Top-10 hit accuracy of 71.6%; median physician accuracy was 72.9% Ubie is effective in providing relevant information based on symptoms, making it valuable in speeding diagnosis and care delivery for improved outcomes The AI-assisted evaluation...
Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024
Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker for predicting efficacy of Nivolumab plus Chemotherapy in advanced gastric cancer, independent of PD-L1 status SEOUL, South Korea, Sept. 10, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today...
IMG Shares Top International Destinations for Autumn 2024
IMG took a sample of its customers and reviewed more than 40,000 travel itineraries of members with upcoming travel plans between September 1st and November 30th of 2024 to determine emerging travel trends this autumn. INDIANAPOLIS, Sept. 10, 2024 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits...
Ractigen Announces Positive Clinical Data for RAG-17 in ALS-SOD1 Treatment from Investigator-Initiated Trial
NANTONG, China and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced promising clinical data from an Investigator-Initiated Trial (IIT) of RAG-17, a small interfering RNA (siRNA) targeting the Superoxide Dismutase 1 (SOD1) gene. The study revealed encouraging results in the treatment of amyotrophic lateral sclerosis (ALS) associated with...
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will hold an extraordinary general meeting of shareholders (the "EGM") at 10:00 a.m., Beijing...
I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling data from three Phase 1 studies providing dosing support for upcoming clinical trials- Exposure-Response (E-R) Analysis showed a positive correlation between uliledlimab concentration and ORR probability in mNSCLC patients- Randomized Phase 2 study of uliledlimab in combination with pembrolizumab plus chemotherapy expected to begin in 1H 2025 ROCKVILLE,...
Updated Data from Phase II Clinical Trial of Iruplinalkib Tablets (Qixinke®) Presented at World Conference on Lung Cancer 2024
JINAN, China, Sept. 10, 2024 /PRNewswire/ -- During the World Conference on Lung Cancer (WCLC) held from September 7-10, 2024, in San Diego, California, updated findings from the Phase II clinical trial (INTELLECT study) were presented. The study assessed the efficacy and safety of Qilu Pharmaceutical's iruplinalkib tablets (Qixinke®) in treating...
The 2024 International (Bozhou) TCM Expo Kicked Off
BOZHOU, China, Sept. 10, 2024 /PRNewswire/ -- On the morning of September 9, the 2024 International (Bozhou) TCM Expo and the 40th National (Bozhou) TCM Trade Fair officially kicked off in Bozhou, Anhui Province. In recent years, Bozhou has been enhancing mechanisms for the inheritance, innovation, and development of Traditional Chinese Medicine (TCM), advancing the modernization and industrialization of...
RingConn Showcases Gen 2 Smart Ring at IFA 2024: Revolutionizing Sleep Monitoring with Integrated Sleep Apnea Detection
BERLIN, Sept. 10, 2024 /PRNewswire/ -- RingConn, a leading personal health technology company, recently showcased its newest innovation—the RingConn Gen 2 Smart Ring—at IFA 2024. This groundbreaking device is the first smart ring to feature integrated sleep apnea monitoring*, redefining smart wearable device. RingConn Gen 2 Smart Ring was initially launched on the Kickstarter crowdfunding platform on August 1,...
